136 results
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
9 May 24
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
7:00am
Volunteer hours (U.S.): 37 Amicus-supported community programs: 32 patients /24countries Expanded Access through Feb 2024: Pricing PROMISE
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
of their work and what they contribute to the community Career Development Reimagined performance management process to measure the what and the how, rewarding … Manufacturing and Related GHG Emissions Diversity, Equity, & Inclusion (DEI) 580 Volunteer hours (U.S.): 22 Amicus-supported community programs: 32
8-K
EX-99.2
vxpldybdjvx
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
S-3ASR
ohjrf0pr npw
8 Nov 23
Automatic shelf registration
5:25pm
8-K
EX-99.2
g3hvn op4
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-10.1
hzqbi
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
1splbe3
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
8-K
EX-99.1
74uagqe6wf5b2xckny2
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
EX-99.1
0zba5hn9oib
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
8-K
EX-99.1
anca8lf bk
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
EX-99.2
fbic7b0750x
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.1
rl5fcu1
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
EX-10.1
kpstna lod1de
12 May 23
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-99.2
irchtg6grje wwo
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
fhuwaqjpxu2wgiwobfyd
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm